To what extent is the new position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) 'personalised'?
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), C/ Rosselló, 149-153, 08036, Barcelona, Spain. aceriell@clinic.ub.es.|Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Spain, . aceriell@clinic.ub.es.
A
A
Ceriello
Oncological Endocrinology, University Hospital San Giovanni Battista, Turin, Italy.
M
M
Gallo
Department of Geriatrics and Metabolic Disease, Second University of Naples, Naples, Italy.
S
S
Gentile
Diabetes and Metabolism Unit, ASL TO5, Chieri, Turin, Italy.
C B
CB
Giorda
Ligurian Health Agency, Genoa, Italy.
A
A
De Micheli
D000465:Algorithms; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005060:Europe; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D011050:Policy Making; D010818:Practice Patterns, Physicians'; D057285:Precision Medicine / Q000639:trends*; D012955:Societies, Medical / Q000639:trends*; D014481:United States
D007004:Hypoglycemic Agents